Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35, 2017 (suppl; abstr LBA9008).
Optimaliseren van behandeling en follow-up bij plaveiselcelcarcinoom van de vulva
okt 2019 | Gynaecologische oncologie